Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1995 May; 88(5): 284P–288P.
PMCID: PMC1295206

Shared care between general practitioners and urologists in the management of benign prostatic hyperplasia: a survey of attitudes among clinicians.


Recent community-based population surveys have revealed a much greater prevalence of benign prostatic hyperplasia than previously suspected. From these data it has been projected that there may be more than 2 million men in the UK whose quality of life is to some extent impaired by this disorder. Since there are only 330 fully trained urologists in this country it will not be feasible for every individual presenting with prostatism to be assessed by a specialist. In an attempt to provide a more rational basis from which family practitioners can decide whether or not to refer a patient for a specialist opinion a 'shared care' flow diagram was developed and assumptions contained within field tested by means of a postal questionnaire which was sent to 2020 urologists, family practitioners and other interested clinicians. There was general agreement with most of the precepts set out in the flow diagram, the main exception was a rejection of the suggestion that every patient with prostatism should have a prostate-specific antigen level determined before referral. We conclude that there seems a consensus among respondents that a shared care approach to the management of BPH may both improve the standard of care provided in this area by family practitioners and allow hard pressed urologists to focus greater attention on those patients whose conditions require surgical expertise to resolve.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (789K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474–479. [PubMed]
  • Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991 Aug 24;338(8765):469–471. [PubMed]
  • Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993 Jul;150(1):85–89. [PubMed]
  • Tsang KK, Garraway WM. Impact of benign prostatic hyperplasia on general well-being of men. Prostate. 1993;23(1):1–7. [PubMed]
  • Duncan BM, Garraway WM. Prostatic surgery for benign prostatic hyperplasia: meeting the expanding demand. Br J Urol. 1993 Nov;72(5 Pt 2):761–765. [PubMed]
  • Barry MJ, Fowler FJ, Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992 Nov;148(5):1549–1564. [PubMed]
  • Hennigan TW, Franks PJ, Hocken DB, Allen-Mersh TG. Rectal examination in general practice. BMJ. 1990 Sep 8;301(6750):478–480. [PMC free article] [PubMed]
  • Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991 May;145(5):907–923. [PubMed]
  • Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991 Apr 25;324(17):1156–1161. [PubMed]
  • Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987 Oct 8;317(15):909–916. [PubMed]
  • Stamey TA, Dietrick DD, Issa MM. Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen. J Urol. 1993 Mar;149(3):510–515. [PubMed]
  • Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992 Apr 22;267(16):2215–2220. [PubMed]
  • Christensen MM, Bendix Holme J, Rasmussen PC, Jacobsen F, Nielsen J, Nørgaard JP, Olesen S, Noer I, Wolf H, Husted SE. Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand J Urol Nephrol. 1993;27(1):39–44. [PubMed]
  • Brawer MK, Adams G, Epstein H. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Arch Fam Med. 1993 Sep;2(9):929–935. [PubMed]
  • Kirby RS, Vale J, Bryan J, Holmes K, Webb JA. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study. Eur Urol. 1993;24(1):20–26. [PubMed]
  • Stoner E. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol. 1992 May;147(5):1298–1302. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press